Vivani Medical, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivani Medical, Inc. on December 27, 2023, regarding events occurring on December 26, 2023. The Company is incorporated in Delaware and its common stock (VANI) trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
On December 26, 2023, the Company received written notice from Nasdaq regarding a failure to satisfy the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Deficiency: The closing bid price of the Common Stock was below $1.00 per share for 30 consecutive trading days (November 9, 2023, through December 21, 2023).
- Current Status: The notice has no immediate effect on listing; the stock continues to trade on the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
Compliance Timeline: The Company has an initial 180-day compliance period ending June 24, 2024. To regain compliance, the closing bid price must be at least $1.00 per share for 10 consecutive trading days prior to this date.
Future Actions: If compliance is not met by June 24, 2024, the Company may be eligible for an additional 180-day period, provided it meets other listing standards (excluding bid price) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split. Any reverse stock split must be completed at least ten business days before the second period expires.
Risks: There is no assurance the Company will regain compliance or that Nasdaq will extend the compliance period. Failure to comply may result in delisting. An appeal to a Nasdaq Hearings Panel is possible but not guaranteed to be successful.
Key Facts for Investor Verification
- Verify the current closing bid price of VANI to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding a potential reverse stock split to address the deficiency.
- Track the June 24, 2024 deadline for the initial compliance period.
- Review subsequent filings for updates on the Company's ability to meet the 10-day consecutive trading requirement.